Last Updated on October 25, 2024 by The Health Master
Wysolone
In a significant development in the pharmaceutical industry, Pfizer, a global pharmaceutical giant, has faced a setback in its challenge against the National Pharmaceutical Pricing Authority (NPPA)’s decision to fix the ceiling price of its steroid drug, Wysolone DT tablets.
The Department of Pharmaceuticals (DoP) has rejected Pfizer’s review application, solidifying the NPPA’s stance on price control for this essential medication.
The Price Control Controversy
The dispute between Pfizer and the NPPA centers around the pricing of Wysolone DT tablets, a prednisolone-based drug used for various medical conditions.
The NPPA, in February 2023, notified the ceiling price of the drug, leading Pfizer to file a review application.
The company argued that the NPPA had erred in determining the ceiling price and sought a revision.
Pfizer’s Arguments and the NPPA’s Stance
Pfizer contended that Wysolone DT was a non-scheduled formulation, having been excluded from the National List of Essential Medicines (NLEM) in 2015.
The company argued that the NPPA had incorrectly classified the drug as a scheduled formulation, leading to an unfair ceiling price.
However, the NPPA maintained that Wysolone DT was indeed covered under the NLEM and was subject to the price control norms.
The Authority emphasized that the drug’s modified release formulation was included within the NLEM’s scope.
The High Court Battle
Pfizer has been engaged in legal proceedings against the NPPA in the High Court of Bombay regarding the price fixation of Wysolone DT.
The company has sought relief from the price control measures, arguing that the innovative nature of the formulation should exempt it from such regulations.
The Review Authority’s Decision
The DoP, acting as the review authority, has now sided with the NPPA. The review authority has upheld the NPPA’s decision to fix the ceiling price of Wysolone DT, rejecting Pfizer’s review application.
This decision reinforces the NPPA’s authority in regulating the prices of essential medicines.
Implications for the Pharmaceutical Industry
The outcome of this case has significant implications for the pharmaceutical industry.
It reaffirms the NPPA’s role in ensuring the affordability of essential medicines in India.
While Pfizer may continue to pursue legal avenues, the decision could set a precedent for other companies seeking to challenge price control measures.
As the pharmaceutical industry evolves, the balance between innovation and affordability remains a critical issue.
The NPPA’s decision in this case underscores the importance of striking the right balance to ensure that essential medicines are accessible to all.
Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.
Two new Drug Testing Laboratories open: Gujarat FDCA
Streamlining Pharma Exports: DGFT Introduces Electronic Submission system
DTAB agrees with proposal to amend New Drugs and Clinical Trials Rules
Drug recall: Gilead recalled this drug after failed trial
FSSAI: Food Labelling and Display – Chapter-11
USFDA approval granted for Fludrocortisone Acetate Tablets
Gujarat FDCA empowers Officers to enforce Revised Schedule M
Govt asks NPPA to recalculate ceiling price of Thiamine Injection
DTAB recommends changes to New Drugs and Clinical Trials Rules
NPPA revised Ceiling price of 11 scheduled formulations: October 2024
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
